GB2082065A - Zootechnic and/or veterinary compositions - Google Patents
Zootechnic and/or veterinary compositions Download PDFInfo
- Publication number
- GB2082065A GB2082065A GB8125267A GB8125267A GB2082065A GB 2082065 A GB2082065 A GB 2082065A GB 8125267 A GB8125267 A GB 8125267A GB 8125267 A GB8125267 A GB 8125267A GB 2082065 A GB2082065 A GB 2082065A
- Authority
- GB
- United Kingdom
- Prior art keywords
- composition
- carbon atoms
- radical
- animals
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 150000003431 steroids Chemical class 0.000 claims abstract description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 20
- FPQFYIAXQDXNOR-QDKLYSGJSA-N alpha-Zearalenol Chemical compound O=C1O[C@@H](C)CCC[C@H](O)CCC\C=C\C2=CC(O)=CC(O)=C21 FPQFYIAXQDXNOR-QDKLYSGJSA-N 0.000 claims abstract description 13
- 229960002300 zeranol Drugs 0.000 claims abstract description 13
- 241000282887 Suidae Species 0.000 claims abstract description 10
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 5
- 241001465754 Metazoa Species 0.000 claims description 22
- -1 alkyl radical Chemical class 0.000 claims description 21
- 239000007943 implant Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 10
- 238000003307 slaughter Methods 0.000 claims description 8
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 7
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 7
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 7
- 229960004544 cortisone Drugs 0.000 claims description 7
- 150000003254 radicals Chemical class 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 238000002513 implantation Methods 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 2
- 210000001217 buttock Anatomy 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 244000144977 poultry Species 0.000 claims description 2
- 230000000384 rearing effect Effects 0.000 claims description 2
- CMRJPMODSSEAPL-FBUBALKHSA-N [(8s,13s,14s)-13-methyl-3-oxo-2,6,7,8,14,15,16,17-octahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC(OC(=O)C)[C@@]1(C)C=C2 CMRJPMODSSEAPL-FBUBALKHSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- MPQOWLNEPUIIBZ-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-1,2,3,6,7,8,14,15,16,17-decahydrocyclopenta[a]phenanthrene Chemical compound C1CC2=CCCCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)C=C2 MPQOWLNEPUIIBZ-SQNIBIBYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- CMRJPMODSSEAPL-FYQPLNBISA-N Trenbolone acetate Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@H](OC(=O)C)[C@@]1(C)C=C2 CMRJPMODSSEAPL-FYQPLNBISA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N alpha-isobutyric acid Natural products CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
- LJOODBDWMQKMFB-UHFFFAOYSA-N cyclohexylacetic acid Chemical compound OC(=O)CC1CCCCC1 LJOODBDWMQKMFB-UHFFFAOYSA-N 0.000 description 2
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentane carboxylic acid Natural products OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 2
- YVHAIVPPUIZFBA-UHFFFAOYSA-N cyclopentaneacetic acid Natural products OC(=O)CC1CCCC1 YVHAIVPPUIZFBA-UHFFFAOYSA-N 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 150000002576 ketones Chemical group 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical group OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- HJZLEGIHUQOJBA-UHFFFAOYSA-N cyclohexane propionic acid Chemical compound OC(=O)CCC1CCCCC1 HJZLEGIHUQOJBA-UHFFFAOYSA-N 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 208000019180 nutritional disease Diseases 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229940115220 zeranol 12 mg Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
- Fodder In General (AREA)
Abstract
The present invention provides zootechnic and/or veterinary compositions which afford excellent results with the growth of pigs, in particular with respect to gain in weight. The compositions of the invention comprise from 10 to 50 mg of zeranol and from 5 to 50 mg of a steroid of the general formula: <IMAGE> wherein R represents an alkyl radical of from 1 to 3 carbon atoms and X represents a hydrogen atom, an acyl radical of from 1 to 18 carbon atoms, a saturated or unsaturated hydrocarbyl radical of from 1 to 6 carbon atoms, or a saturated or unsaturated hydrocarboxyhydrocarbyl radical of from 2 to 5 carbon atoms.
Description
SPECIFICATION
Zootechnic and/or veterinary compositions
The present invention relates to zootechnic and/or veterinary compositions, and in particular to compositions containing zeranol and a steroid.
In our co-pending Application No. 16,685/78 (Serial No. 1,597,619) there are described and claimed zootechnic and/orveterinary compositions comprising zeranol and a steroid of the general formula:
wherein R represents an alkyl radical containing
from 1 to 3 carbon atoms and X represents a hyd
rogen atom, an acyl radical of from 1 to 18 carbon
atoms, a saturated or unsaturated hydrocarbyl radi
cal of from 1 to 6 carbon atoms or a saturated or
unsaturated hydrocarboxyhyd roca rbyl radical of
from 2 to 5 carbon atoms, optionally together with
one or more substances included to improve the
reabsorption characteristics of the compositions, in
particular an anti-inflammatory compound.
The above compositions are intended to promote
an increase in weight in stock animals such as cattle
and pigs. The simultaneous presence of two active
agents reinforces in an unexpected manner the
favourable action on the growth of the animals of
each of the active agents such that the resulting
increase in weight is considerably greater than that
which might have been expected, taking account of
the known properties of each active agent.
For cattle, and especially bullocks, the earlier dis
closure indicates that such compositions advan
tageously contain from 10 to 100 mg and, preferably,
from 20 to 60 mg ofzeranol and from 50 to 400 mg,
and preferably from 100 to 300 mg, of a steroid of
formula I. For their administration to livestock, the
above compositions can be deposited in the form of
an implant in the dermis, preferably at the base of
the ear. The implant is preferably deposited in cattle,
for example, from 20 days to 4 months, and more
preferably from 1 to 3 months, before slaughter.
Application No. 16,685178 describes in a general
way all combinations containing zeranol and a
steroid of formula I, and while it does also described - in a more particular manner the combinations men
tioned above, the earlier Application basically is
concerned in its more particular aspects with com
positions containing a much greater quantity of a
steroid of the formula I than of zeranol.
We have now found surprisingly that excellent
results with the growth of pigs can be obtained, in
particular with respect to gain in weight, by administering to pigs a composition in which the amount of steroid of formula I is less than that proposed earlier.
Accordingly, the present invention provides zootechnic and/or veterinary compositions, which compositions comprise from 10 to 50 mg, of zeranol and from 5 to 50 mg, preferably 5 to less than 50 mg, of a steroid of the general formula:
wherein R represents an alkyl radical of from 1 to 3 carbon atoms and X represents a hydrogen atom, an acyl radical of from 1 to 18 carbon atoms, a saturated or unsaturated hydrocarbyl radical of from 1 to 6 carbon atoms, or a saturated or unsaturated hydrocarboxyhydrocarbyl radical of from 2 to 5 carbon atoms, that is a radical in which one ofthe carbon atoms of a saturated or unsaturated hydrocarbyl radical of from 1 to 6 carbon atoms is replaced by an oxygen atom.
In the steroids of general formula I, when X represents a saturated hydrocarbyl radical this may be a methyl, ethyl, propyl,ísopropyl, butyl orisobutyl radical. When X represents an unsaturated hydrocarbyl radical this may be an alkenyl or an alkynyl radical; and the preferred alkenyl radical is a 2-methyl-al lyl or 3-methyl-2-butenyl radical.
When X represents a hydrocarboxyhydrocarbyl radical this may be saturated or unsaturated and a preferred radical is the methoxymethyl radical.
As an acyl radical, X is preferably derived from an alkanoic acid such as acetic, propionic, butyric, Isobutyric or undecylic acid, from a cycloalkylcarboxylic or cycloalkylalkanoic acid such as cyclopropyl-, cyclopentyl- or cyclohexylcarboxylic acid, cyclopropyl-, cyclopentyl- or cyclohexylacetic acid or cyclopropyl-, cyclopentyl- or cyclohexylpropionic acid, from an aromatic acid such as benzoic, phenylacetic or phenylpropionic acid or from formic acid.
Preferred compositions according to the invention are those which contain a steroid of formula I in which R represents a methyl radical, and those which contain a steroid of formula I in which X represents an acyl radical of from 1 to 18 carbon atoms.
More preferably the compositions of the invention are those wherein the steroid of formula I is 3 - oxo 17ss- acetoxy - estra - 4,9,11 - triene.
Preferably also the compositions of the invention are compositions which contain from 10 to 40 mg of zeranol, together with from 10 to 30 mg of 3 - oxo 17p- acetoxy - estra - 4,9,11 - triene. In particular, the compositions are most preferably those that contain from 10 to 40 mg of zeranol and 20 mg of 3 - oxo 17ss- acetoxy - estra - 4,9,11 - triene.
As has been pointed out above, the compositions of the invention enable very good results to be obtained with pigs. Thus the compositions of the invention preferably are such as may be administered to pigs.
It is to be understood, however, that the compositions of the invention are not limited to those that can only be administered to pigs; the compositions of the invention in their broadest use aspect can also be administered, for example, to cattle, sheep and poultry.
The compositions of the invention are preferably administered in the form of implants. These implants may be placed in the neck of the animal or in the buttock muscles and are implanted, for exam ple, from 20 days to 4 months, preferably from 1 to 3 months, before slaughter.
The compositions according to the invention also may be administered by injection, and for that purpose may be in the form of solutions or suspensions, or they may be administered orally. Implants, however, offerthe advantage of being better resorbed.
The compositions of the invention also exhibit useful pharmacological properties, in particular anabolizing properties and, more particularly, proteinic anabolizing properties. These properties make the compositions according to the invention suitable for use also as veterinary medicaments, particularly for augmenting a general organic resistance to attacks of all kinds, combating retardation of growth, emaciation, general organic troubles connected with old age, and equally for combating in a secondary manner infectious, parasitic and nutritional diseases.
In veterinary use the compositions of the invention may be mixed with other ingredients of veterinary compositions as knownperse, the content of active principles of the composition according to the invention in the overall formulation varying according to the animal species.
For example, other active materials may be incorporated in the compositions of the invention for the purpose of increasing resorbtion of the compositions. Amongst these active materials, and particularly useful for compositions intended for implantation, are anti-inflammatory compounds and preferably steroids of the cortisone type.
The expression "steroids of the cortisone type" is used herein to mean a steroid having antiinflammatory properties similar two cortisone and bearing a ketone function at the 3 position of the steroid nucleus, a hydroxy group or a ketone function at the 11 position, a free or esterified ketol chain at the 17ss position and a hydrogen atom our a hydroxygroup atthe 17a position, with either one or two double bonds in the A ring; the steroid nucleus may also bear other substituents such as a chlorine or fluorine atom at the 4 position, a methyl or a trifluoromethyl group or a halogen atom such as fluorine at the 6 position, a halogen atom such as fluorine at the 9 position, a methyl group at the 1 spa or 1 6ss position or a methylene group at the 16 position, and a methylene or difluoromethylene bridge between the 6 and 7 positions.
The preferred steroid of the cortisone type for inclusion in the compositions ofthe invention is dexamethasone - (ss- ethoxy - ss- ethoxy) - ethoxy acetate.
The compositions ofthe invention may preferably contain from 0.05 to 5 mg of a steroid of the cortisone type.
In some circumstances, it may be desirable for the compositions of the invention to include a suitable vehicle. The term "suitable vehicle" is used herein to exlude any possibility that the nature of the vehicle could be harmful to the animal being treated. The choice of vehicle will of course also be determined by the route by which it is intended to administerthe composition, and it is believed to be within the competence of those accustomed to the preparation of formulations of this type to make such a choice.
Preferred vehicles for use in the compositions of this invention are:
a) the excipient of a tablet, pellet, implant or pill;
b) a sterile injectable liquid solution or suspension medium.
The compounds utilized in the compositions according to the invention are known per se; zeranol orzearalanol (see Merck Index 1976,9th edition 9781) can be prepared, for example, according to the process described in U.S. Patent Specification No.
3,239,345.
Compounds of formula I can be prepared according to processes described in French Patent Specifications Nos. 1,380,414 and 1,492,985, as well as in
Belgian Patent Specification No.696,084.
The invention also includes a method of animal husbandry, which method comprises rearing one or more animals to achieve an increase in weight and thereafter slaughtering the animals, the method including the step of administering to the animals a composition according to the invention.
The following examples illustrate the invention, without, however, limiting it:
Example 1: Zootechnic composition in the form of an implant.
An implant was prepared containing:
zeranol 36 mg
3-oxo 17pacetoxy estra 4,9,11-triene 20 mg
Example 2: Zootechnic composition in the form of an implant
An implant was prepared containing:
zeranol 24 mg
3-oxo 17ssacetoxy estra 4,9,11-triene 20 mg
Example 3: Zootechnic composition in the form of an implant
An implant was prepared containing:
zeranol 12 mg
3-oxo 17ss-acetoxy estra 3,9,11-triene 20 mg
Example 4: Comparison of effects on animals of var ious zootechnic compositions.
This test was carried out on castrated male
Large-White-Landrace pigs. The animals were fattened in industrial-type piggeries and housed in enclosures able to contain 7 to 10 pigs. The animals were divided into 4 groups:
one control group;
one group to which the implant of Example 1 was administered;
one group to which the implant of Example 2 was administered; and
one group to which the implant of Example 3 was administered.
The implants were introduced into the subcutaneous tissue behind the ear, 63 days before slaughter. All the animals received the same foodstuff and the results obtained are set out in Tablet below:
Table 1
Animals Treatment Controls Those having received the implant of Example 1 2 3 Period in days before slaughter 63 63 -63 63 Group No. 1 2 3 4 Number of animals 15 14 15 14 Number of days of fattening 63 63 63 63 Mean weight on day of treatment (Kg) 65.53 65.07 64.67 65.00 Mean weight at the end of the test (Kg) 101.40 102.79 106.13 102.36 Mean gain in weight (Kg) 35.87 37.72 41.46 37.36 Mean daily gain in weight (Kg) 0.569 0.599 0.658 0.593 I As can be seen from Table 1 the compositions of
Examples 1,2 and 3 enable the daily gain in weight to be very clearly improved.
Claims (20)
1. Azootechnic and/orveterinary composition, which composition comprises from 10 to 50 mg of zeranol and from 5 to 50 mg of a compound of the formula:
wherein R represents an alkyl radical offrom 1 to 3 carbon atoms and X represents a hydrogen atom, an acyl radical of from 1 to 18 carbon atoms, a saturated or unsaturated hydrocarbyl radical of from 1 to 6 carbon atoms or a saturated or unsaturated hydrocarboxyhydrocarbyl radical of from 2 to 5 carbon atoms.
2. A composition according to claim 1, wherein the compound of formula I is one in which R represents a methyl radical.
3. Acomposition according to claim 1 or claim 2, wherein the compound offormula I is one in which X represents an acyl radical of from 1 to 18 carbon atoms.
4. Acomposition according to claim 3, wherein the compound of the formula I is 3 - oxo - 17 - acetoxy - estra - 4,9,11 - triene.
5. A composition according to any one of the preceding claims, which contains from 10 to 40 mg of zeranol and from 10 to 30 mg of 3 - oxo - 17,B - acetoxy - estra - 4,9,11 - triene.
6. A composition according to claim 5, which contains from 10 to 40 mg ofzeranol and 20 mg of 3 oxo - 17jB- acetoxy - estra - 4,9,11 - triene.
7. A composition as claimed in any of the preceding claims which also contains an anti-inflammatory compound.
8. A composition as claimed in claim 7, in which the anti-inflammatory compound is a steroid of the corisone type as hereinbefore defined.
9. A composition as claimed in claim 8, in which the steroid of the cortisone type is dexamethasone (Xss - ethoxy - ,8 - ethoxy) - ethoxy acetate.
10. A composition as claimed in claim 8 or claim 9 and containing 0.05 to 5 mg of the steroid of the cortisone type.
11. A composition according to any one of the preceding claims which also includes a suitable vehicle.
12. A zootech nic and/or veterinary composition substantially as hereinbefore described in any one of specific Examples 1 to 3.
13. A method of animal husbandry, which method comprises rearing one or more animals to achieve an increase in weight and thereafter slaughtering the animals, the method including the step of administering to the animals a composition according to any one ofthe preceding claims.
14. A method according to claim 13, wherein the animals reared are pigs.
15. A method according to claim 13, wherein the animals reared are cattle, sheep or poultry.
16. A method according to any one of claims 13 to 15, wherein the composition is administered as an implant.
17. A method according to claim 16, wherein the implant is placed in the neck of the animal or in the buttock muscles.
18. Amethod according to claim l6orclaim 17, wherein implantation is effected at a time from 20 days to 4 months before slaughter.
19. A method according to claim 18, wherein implantation is effected at a time from 1 to 3 months before slaughter.
20. A method according to claim 13 substantially as hereinbefore described specifically.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8018107A FR2488799A2 (en) | 1980-08-19 | 1980-08-19 | ZOOTECHNIC COMPOSITIONS COMPRISING ZERANOL ON THE ONE HAND AND STEROID ON THE OTHER 4, 9, 11-TRIENIC |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB2082065A true GB2082065A (en) | 1982-03-03 |
| GB2082065B GB2082065B (en) | 1985-02-13 |
Family
ID=9245264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB8125267A Expired GB2082065B (en) | 1980-08-19 | 1981-08-19 | Zootechnic and/or veterinary compositions |
Country Status (12)
| Country | Link |
|---|---|
| BE (1) | BE890004R (en) |
| BG (1) | BG45693A3 (en) |
| CA (1) | CA1166568A (en) |
| DD (1) | DD201564A5 (en) |
| DE (1) | DE3132817A1 (en) |
| FR (1) | FR2488799A2 (en) |
| GB (1) | GB2082065B (en) |
| IE (1) | IE51504B1 (en) |
| IT (1) | IT1171471B (en) |
| LU (1) | LU83561A1 (en) |
| NL (1) | NL193720C (en) |
| SU (1) | SU1153811A3 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7999005B2 (en) | 1998-11-04 | 2011-08-16 | Schering-Plough Animal Health Corporation | Growth stimulant compositions |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2388560A1 (en) * | 1977-04-27 | 1978-11-24 | Roussel Uclaf | NEW ZOOTECHNICAL COMPOSITIONS CONTAINING ON THE ONE HAND ZERANOL AND ON THE OTHER HAND A STEROID 4,9,11 TRIENIQUE |
-
1980
- 1980-08-19 FR FR8018107A patent/FR2488799A2/en active Granted
-
1981
- 1981-07-24 SU SU813311254A patent/SU1153811A3/en active
- 1981-08-07 BG BG53221A patent/BG45693A3/en unknown
- 1981-08-14 DD DD81232611A patent/DD201564A5/en not_active IP Right Cessation
- 1981-08-18 NL NL8103855A patent/NL193720C/en not_active IP Right Cessation
- 1981-08-18 CA CA000384092A patent/CA1166568A/en not_active Expired
- 1981-08-18 BE BE0/205703A patent/BE890004R/en not_active IP Right Cessation
- 1981-08-18 IT IT49126/81A patent/IT1171471B/en active
- 1981-08-18 LU LU83561A patent/LU83561A1/en unknown
- 1981-08-19 GB GB8125267A patent/GB2082065B/en not_active Expired
- 1981-08-19 DE DE19813132817 patent/DE3132817A1/en active Granted
- 1981-08-19 IE IE1901/81A patent/IE51504B1/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7999005B2 (en) | 1998-11-04 | 2011-08-16 | Schering-Plough Animal Health Corporation | Growth stimulant compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| BG45693A3 (en) | 1989-07-14 |
| GB2082065B (en) | 1985-02-13 |
| NL8103855A (en) | 1982-03-16 |
| DE3132817C2 (en) | 1992-04-09 |
| CA1166568A (en) | 1984-05-01 |
| IE811901L (en) | 1982-02-19 |
| NL193720B (en) | 2000-04-03 |
| IE51504B1 (en) | 1987-01-07 |
| FR2488799B2 (en) | 1983-10-28 |
| DD201564A5 (en) | 1983-07-27 |
| LU83561A1 (en) | 1982-04-14 |
| FR2488799A2 (en) | 1982-02-26 |
| IT8149126A0 (en) | 1981-08-18 |
| NL193720C (en) | 2000-08-04 |
| DE3132817A1 (en) | 1982-04-29 |
| IT1171471B (en) | 1987-06-10 |
| SU1153811A3 (en) | 1985-04-30 |
| BE890004R (en) | 1982-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU203667B (en) | Process for producing synergetic zootechnical compositions containing three components | |
| Karasawa et al. | Role of caeca in the nitrogen nutrition of the chicken fed on a moderate protein diet or a low rotein diet plus urea | |
| US4192870A (en) | Novel zootechnical compositions | |
| Vernon et al. | The effect of trenbolone acetate with time on the various responses of protein synthesis of the rat | |
| Walker et al. | Premature death with bladder outlet obstruction and hyperprolactinemia in new zealand black× new zealand white mice treated with ethinyl estradiol and 17 beta—estradiol | |
| GB2082065A (en) | Zootechnic and/or veterinary compositions | |
| EP0015637B1 (en) | Method for enhancing growth rate and feed efficiency of ruminants | |
| US3939265A (en) | Novel zootechnical compositions | |
| Kenney et al. | Livestock hormones in the United States | |
| DE1767274A1 (en) | Thiouracilcarboxylic acids, their non-toxic salts or alkyl esters | |
| US5147869A (en) | Zootechnical compositions | |
| US3009857A (en) | Method of growth improvement in meat producing animals | |
| Heitzman | The use of hormones to regulate the utilization of nutrients in farm animals: current farm practices | |
| Lin et al. | Gossypol pharmacokinetics in mid-lactation Brown Swiss dairy cows | |
| DE2449653C2 (en) | Animal fattening agents | |
| Franco et al. | Hormones | |
| AU598898B2 (en) | Methods for suppressing the endocrine system | |
| US20230263189A1 (en) | Additive for animals that contain saponins, phenolic compounds and p-cimenol, and procedure for its obtention | |
| KR102588133B1 (en) | Ordor reducing composition | |
| JPS6017770B2 (en) | Composition for animal fattening | |
| Heitzman | Anabolic agents in beef production: Their action as growth promoters | |
| Allen et al. | A biochemical study of experimental Johne's disease: II. An in vitro study of L-histidine uptake by sheep intestinal mucosa | |
| Willemart et al. | A RAL compound as an anabolic in cattle | |
| Haenel | Biological results with synthetic mustard oil-splitting substances | |
| Bartnikowska et al. | Dynamics of absorption of dietary cholesterol from the alimentary tract as influenced by pectin in pigs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20000819 |